Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02696889 |
Recruitment Status :
Completed
First Posted : March 2, 2016
Last Update Posted : September 23, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Ovarian Insufficiency Low Ovarian Reserve Premature Ovarian Failure | Procedure: ROSE-1 Protocol | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 3 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Autologous Stem Cell Therapy for Premature Ovarian Insufficiency and Low Ovarian Reserve |
Actual Study Start Date : | February 6, 2016 |
Actual Primary Completion Date : | May 6, 2021 |
Actual Study Completion Date : | May 6, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: ROSE-1 Protocol
Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
|
Procedure: ROSE-1 Protocol
A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur. |
- Improved diagnostic hormonal levels [ Time Frame: 18 months ]Reduction of 50% in FSH values; increase in AMH and Estradiol levels (30%)
- Resumption of menses [ Time Frame: 18 months ]Resumption of menses. Improved quality of life using the North American Menopausal Society (NAMS) validated menopause health questionnaire.
- Improved clinical hormone levels [ Time Frame: 18 months ]Improvement in hormonal levels toward normal ranges. Hormones may include FSH/LH; Estradiol/ progesterone;Inhibin; Anti- Mullerian Hormone
- Achievement of pregnancy [ Time Frame: 18 months ]Achievement of pregnancy by natural or assisted conception methods as may be deemed appropriate by the patient and her primary provider.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
- Able to understand and communicate in English language
- Signed and dated informed consent
- Female over the age of 18
- Diagnosis of premature ovarian insufficiency: At least two menopausal FSH levels (≥ 40 IU/L) and/or Primary or secondary amenorrhea at least for 3-6 months OR Diagnosis of low ovarian reserve defined as: AMH < _0.42 ng/ML & FSH >20 IU/L, and/or failure of prior attempts of assisted reproductive techniques due to limited ovarian response (poor responder).
- Normal karyotype 46, XX.
- Presence of at least one ovary
- Acceptable uterine anatomy (by any clinically and/or imaging acceptable methods)
- Normal thyroid function as evidence by normal serum Thyroid Stimulating Hormone (TSH) levels.
- Agree to report any pregnancy to the research staff immediately.
- Willing and able to comply with study requirements and follow up instructions.
- No other causes of female infertility in the subject
If subject is planning to pursue pregnancy: Presence of at least unilateral tubal patency (with any clinically acceptable methods).
Exclusion Criteria
- Unable to understand and communicate in English language
- Currently pregnant or breast-feeding
- Has a history of, or evidence of current gynecologic malignancy within the past three years
- Presence of adnexal masses indicating the need for further evaluation
- Major mental health disorder that precludes participation in the study
- Active substance abuse or dependence
- Unfit or unwilling to undergo laparoscopy; has contraindication to laparoscopic surgery and/or general anesthesia
- Current or recent (within the past 2 weeks) use of the following medications: Oral or systemic corticosteroids, Hormones (estrogen, progestins, oral contraceptives), Danazol, anticoagulants, herbal or botanical supplements with possible hormonal effects. Washout will be allowed.
- Medical conditions that are contraindicated in pregnancy
- Type I or Type II diabetes mellitus, or if receiving antidiabetic medications
- Known significant anemia (Hemoglobin <8 g/dL).
- Untreated deep venous thrombosis, and/or pulmonary embolus
- Untreated cerebrovascular disease
- Known heart disease (New York Heart Association Class II or higher).
- Known Liver disease (defined as Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT)>2 times normal, or total bilirubin >2.5 mg/dL).
- Known Renal disease (defined as Blood urea nitrogen (BUN)>30 mg/dL or serum creatinine > 1.6 mg/dL).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02696889
United States, Illinois | |
University of Illinois at Chicago | |
Chicago, Illinois, United States, 60607 |
Principal Investigator: | Ayman Al-Hendy, MD, PhD | University of Illinois at Chicago |
Responsible Party: | Ayman Al-Hendy, Professor of Obstetrics and Gynecology, University of Illinois at Chicago |
ClinicalTrials.gov Identifier: | NCT02696889 |
Other Study ID Numbers: |
2018-0277 |
First Posted: | March 2, 2016 Key Record Dates |
Last Update Posted: | September 23, 2021 |
Last Verified: | September 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Infertility Premature Ovarian Failure Stem Cells Amenorrhea |
Low Ovarian Reserve Ovarian Insufficiency Premature menopause Premature Ovarian Insufficiency |
Premature Birth Primary Ovarian Insufficiency Menopause, Premature Obstetric Labor, Premature Obstetric Labor Complications |
Pregnancy Complications Ovarian Diseases Adnexal Diseases Gonadal Disorders Endocrine System Diseases |